• Acute Myeloid Leukemia

Dr. Meshinchi’s clinical and research interests center around the treatment of pediatric myeloid leukemia. He is the principal investigator on ten research projects at FHCRC and Seattle Children’s, including a study on the biology of the alterations of the signal transduction pathway in pediatric cancers, the biology and prognostic implications of FLT3 mutations in AML and the evaluation of minimal residual disease by multiparameter flow cytometry for risk identification.